Richard Hallam

Richard Hallam has over 20 years of experience in the biotechnology industry. From 2013 to present, they have been the Eastern Business Development North America at AnaBios Corporation. In this role, they have offered clients and partners access to an extensive battery of assays and technologies to study ex-vivo human responses to drugs and investigate the molecular and functional basis of human physiology. Richard has also leveraged the company's technology to advance the scientific exploration of human biology and the advancement of human health. From 2000 to 2013, Richard Hallam worked at Geneka QC Canada as a Biotech. Richard's focus included genomic sales and genomic contract research sales for gene expression profiling, transcription factors, promoter analysis, DNAse I footprinting, nuclear, cytoplasmic, whole cell and RNA extractions, EMSA gel-shifting kits, northern blotting kits, western blotting kits, antibodies for EMSA super shifting, PCR enzymes, RNA & SDS-page membranes, genetic mutation discovery instrumentation, and instrumentation consumables.

Richard Hallam holds a Bachelor's degree in Biochemistry from Concordia University, as well as a Bachelor of Science in Biochemistry and Molecular Biology from the same university.